Summit Partners Public Asset Management’s Ascendis Pharma A/S ASND Stock Holding History

Summit Partners Public Asset Management’s Portfolio ASND Stock Details ASND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-130,700	Closed	-$17.8M	–	114
2024 Q2	$17.8M	Buy	130,700 +55,600	+74%	+$7.57M	0.68%	51
2024 Q1	$11.4M	Buy	+75,100	New	+$10.7M	0.39%	77

Other funds holding ASND

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Summit Partners Public Asset Management's ASND Position: Q4 2025 in Review

Summit Partners Public Asset Management sold out of Ascendis Pharma A/S (ASND) in Q4 2025, closing a stake of 100,000 shares — an estimated $19.9M sold.

Summit Partners Public Asset Management first reported a position in ASND in Q1 2022 and held it in 8 quarters. The position peaked at $34M in Q1 2024. 302 funds tracked by Wall St. Rank hold ASND as of Q4 2025.

Summit Partners Public Asset Management reported no remaining Ascendis Pharma A/S position as of Q4 2025 after selling out during the quarter.
Summit Partners Public Asset Management sold 100,000 Ascendis Pharma A/S shares in Q4 2025, an estimated $19.9M.
Summit Partners Public Asset Management first reported a position in Ascendis Pharma A/S in Q1 2022 and held it in 8 quarters.
Summit Partners Public Asset Management's Ascendis Pharma A/S position peaked at $34M in Q1 2024.
302 funds tracked by Wall St. Rank held Ascendis Pharma A/S as of Q4 2025.

Based on Summit Partners Public Asset Management's 13F filing for Q4 2025, filed 17 Feb 2026.